###begin article-title 0
###xml 65 72 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 160 166 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 148 152 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR</italic>
###xml 333 340 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 394 409 390 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A, FCGR2B </italic>
###xml 413 419 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 469 474 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 571 577 567 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 579 586 575 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 590 597 586 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 719 726 715 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 844 849 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 1097 1112 1093 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A, FCGR2B </italic>
###xml 1116 1123 1112 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 1228 1242 1224 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 1314 1316 1310 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1480 1482 1476 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1664 1671 1660 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 1755 1769 1751 1765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 1827 1834 1823 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 1837 1843 1833 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 1556 1564 <span type="species:ncbi:9606">patients</span>
The Fcgamma receptors play important roles in the initiation and regulation of many immunological and inflammatory processes, and genetic variants (FCGR) have been associated with numerous autoimmune and infectious diseases. The data in rheumatoid arthritis (RA) are conflicting and we previously demonstrated an association between FCGR3A and RA. In view of the close molecular proximity with FCGR2A, FCGR2B and FCGR3B, additional polymorphisms within these genes and FCGR haplotypes were examined to refine the extent of association with RA. Biallelic polymorphisms in FCGR2A, FCGR2B and FCGR3B were examined for association with RA in two well characterized UK Caucasian and North Indian/Pakistani cohorts, in which FCGR3A genotyping had previously been undertaken. Haplotype frequencies and linkage disequilibrium were estimated across the FCGR locus and a model-free analysis was performed to determine association with RA. This was followed by regression analysis, allowing for phase uncertainty, to identify the particular haplotype(s) that influences disease risk. Our results reveal that FCGR2A, FCGR2B and FCGR3B were not associated with RA. The haplotype with the strongest association with RA susceptibility was the FCGR3A-FCGR3B 158V-NA2 haplotype (odds ratio 3.18, 95% confidence interval 1.13-8.92 [P = 0.03] for homozygotes compared with all genotypes). The association was stronger in the presence of nodules (odds ratio 5.03, 95% confidence interval 1.44-17.56; P = 0.01). This haplotype was also more common in North Indian/Pakistani RA patients than in control individuals, but not significantly so. Logistic regression analyses suggested that FCGR3A remained the most significant gene at this locus. The increased association with an FCGR3A-FCGR3B haplotype suggests that other polymorphic variants within FCGR3A or FCGR3B, or in linkage disequilibrium with this haplotype, may additionally contribute to disease pathogenesis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 853 854 853 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 971 972 971 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1012 1013 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
Rheumatoid arthritis (RA) is a heterogeneous disease characterised by a chronic, fluctuating, peripheral, symmetrical and erosive polyarthritis. It has been reported throughout the world, with a prevalence rate of approximately 1% in most populations [1]. Persistent synovial inflammation leads to progressive joint destruction, which in turn produces deformity and significant disability. In addition, RA is a systemic disease and some patients develop subcutaneous rheumatoid nodules, secondary Sjogren's syndrome, episcleritis and scleritis, interstitial lung disease, pericardial involvement, systemic vasculitis and Felty's syndrome. These extra-articular manifestations of RA appear to be rare in the absence of rheumatoid factor (RF), and IgG RF titres correlate with articular disease severity and with the extra-articular manifestations of RA [2]. In addition to RF, many other IgG autoantibodies are found in RA, most notably anti-cyclic citrullinated peptide [3] and anti-type II collagen antibodies [4].
###end p 4
###begin p 5
###xml 770 771 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 772 773 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 896 897 864 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1184 1185 1152 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1408 1409 1368 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1633 1634 1585 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1635 1637 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 234 240 <span type="species:ncbi:9606">humans</span>
###xml 1450 1455 <span type="species:ncbi:10090">mouse</span>
The Fcgamma receptors (FcgammaRs), which bind these IgG autoantibodies and IgG-containing immune complexes, have been shown to play important roles in the initiation and regulation of many immunological and inflammatory processes. In humans, there are three classes of FcgammaRs (I-III) encoded by eight genes, which produce at least 15 different membrane-bound and soluble isoforms that vary in their cellular distribution and affinity for different IgG isotypes. This molecular and expression diversity restricts specific biological properties to certain cell types. Activating (FcgammaRIIa, FcgammaRIIIa and FcgammaRIIIb) and inhibitory (FcgammaRIIb) FcgammaRs are frequently coexpressed on the same cell, thus providing a means for regulating signalling thresholds [5,6]. Furthermore, the absolute level of receptor expression is modulated by proinflammatory and anti-inflammatory cytokines [7]. Activating functions include uptake and clearance of immune complexes (complement dependent and independent mechanisms), activation of phagocytes (trigger the oxidative burst, cytotoxic granule and cytokine release), antigen presentation and antibody-dependent cellular cytotoxicity [6]. Conversely, FcgammaRIIb contains an inhibitory motif in the cytoplasmic tail and abrogates cellular activation. FcgammaRIIb may also play a role in maintaining peripheral B cell tolerance and prevention of autoimmunity [8]. Single and multiple FcgammaR knockout mouse models have demonstrated that the balance between activating and inhibitory FcgammaRs influences the development of both immune complex-mediated and collagen-induced arthritis [9,10].
###end p 5
###begin p 6
###xml 353 360 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 771 777 771 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 860 866 860 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1451 1458 1451 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 1714 1716 1714 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1717 1719 1717 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
Polymorphic variants that increase the expression or affinity of these IgG receptors or that enhance their ability to bind specific IgG isotypes may therefore play an important role in determining the severity and persistence of inflammation to IgG (auto)antibodies and immune complexes in RA. Our previous studies have supported an association between FCGR3A and RA. The higher affinity FCGR3A-158V allele was associated with an increased susceptibility to RA, with homozygotes demonstrating a 1.5-fold to twofold increased risk for RA and a twofold to fourfold increase in nodules [11,12]. In keeping with several other RA susceptibility genes, this association has not been replicated in all populations [13-18]. There was a trend toward an increased frequency of the FCGR3A-158V allele in Norwegian and Dutch RA patients [16,18], with a skewing toward the FCGR3A-158F allele in Spanish, Japanese and Indian populations [13-15,17]. Many reasons for the lack of reproducibility of association studies have been proposed and include differences in the design, power and accuracy of genotyping strategies in the various studies. The apparently conflicting results may also be a consequence of a genuine difference in the genetic and environmental susceptibility factors according to the precise ethnic group or disease phenotype under investigation. Nonreplication may thus indicate a real biological difference between populations. Alternatively, if FCGR3A is in linkage disequilibrium with the true RA-susceptibility locus then, because the extent of linkage disequilibrium varies between different populations, the association may only exist in certain populations and contribute to nonreplication of findings [12,19].
###end p 6
###begin p 7
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 110 117 110 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 418 425 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 511 516 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 706 720 706 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 785 792 785 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 795 801 795 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
FCGR3A lies in a 200 kilobase FCGR gene cluster on 1q22-23 in close molecular proximity to FCGR2A, FCGR3B and FCGR2B [20]. Functional single nucleotide polymorphisms (SNPs) in the latter genes have been investigated as genetic susceptibility and severity factors in multiple infectious and autoimmune diseases [5,6]. We therefore undertook additional genotyping in our original RA cohorts and examined SNPs in FCGR2A, FCGR2B and FCGR3B; examined the extent of linkage disequilibrium at this locus; and analyzed FCGR haplotypes for association with disease in order to investigate the possibility that there are other RA susceptibility variants at this locus. We demonstrate an increased association with a FCGR3A-FCGR3B haplotype, which suggests that other polymorphic variants within FCGR3A or FCGR3B, or in linkage disequilibrium with this haplotype may additionally contribute to disease pathogenesis.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Rheumatoid arthritis patients and control individuals
###end title 9
###begin p 10
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 175 182 175 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
This was an allelic association study conducted to examine FCGR2A, FCGR2B and FCGR3B, and FCGR haplotypes in two well characterized RA cohorts in which an association between FCGR3A and RA was previously identified [11]. The recruitment and clinical characteristics of these two RA and control populations, resident in Birmingham, UK have previously been described [11,21]. They comprise 294 UK Caucasian individuals (150 RA patients and 144 healthy control individuals) and 256 North Indian/Pakistani individuals (126 RA patients and 130 healthy control individuals). Ethical approval was obtained from the respective local research ethics committees.
###end p 10
###begin title 11
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Elucidation of the FCGR gene order
###end title 11
###begin p 12
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 294 300 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 302 309 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 313 319 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
###xml 336 343 336 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Computational assemblies of 1q23 at the National Center for BioInformatics [22], Ensembl [23] and Oak Ridge National Laboratory [24] websites resulted in several variations in FCGR gene order, thus necessitating the construction of an electronic contig. Genomic exon sequences of the class II (FCGR2A, FCGR2B and FCGR2C) and class III (FCGR3A and FCGR3B) genes were aligned to enable identification of homologous regions and specific nucleotides that distinguished the FCGR genes. All available sequence data containing the class II and III FCGR genes was identified by performing BLAST (basic local alignment search tool) sequence homology searches at the National Centre for BioInformatics [22] using five 30-base-pair homologous regions from each receptor class. The bacterial artificial chromosome (BAC) sequence fragments were primarily aligned by the identification of complete gene sequences and overlapping sequence data from neighbouring BACs, and the final assembly was facilitated by utilizing published restriction enzyme maps of this locus [20,25].
###end p 12
###begin title 13
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
FCGR2B sequence analysis
###end title 13
###begin p 14
###xml 84 91 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 403 405 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 666 672 660 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
At the time when this study was performed, several putative polymorphic variants of FCGR2B had been identified in a cDNA library [26], but these had not been substantiated by sequencing genomic DNA. These included a 2-base-pair deletion at positions 208-210 at the start of exon 3, a G-->A substitution at position 685 in exon 4, a functionally significant T-->G substitution at position 855 in exon 6 [27] and a G-->A substitution at position 1206 in the 3'-untranslated region (UTR). Two potential polymorphic sites (rs844 and rs1043) in STS accession G06355 (UniSTS:73835) were also identified from the reference SNP database, which corresponded to the 3'-UTR of FCGR2B.
###end p 14
###begin p 15
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 60 75 60 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A, FCGR2C </italic>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 449 451 447 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1083 1087 1057 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1193 1197 1165 1167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
The genomic sequence alignments of the class II FCGR genes (FCGR2A, FCGR2C and FCGR2B), generated as described above, were used to design FCGR2B-specific PCRs to facilitate direct sequencing of exons 3 and 6 and the 3'-UTR. The primer sequences and annealing temperatures of the different PCR reactions are shown in Table 1. Briefly, 20 mul PCRs were performed using 100 ng DNA, 200 nmol/l of each primer, 40 mumol/l each of 4 dNTPs, 1.5 mmol/l MgCl2 and 0.5 units of Taq DNA polymerase (Promega, Southampton, UK). The PCR reaction was performed in 30 individuals using a Techne Genius PCR machine (Techne [Cambridge] Ltd, Ducksford, Cambridge, UK) and the PCR conditions were 95degreesC for 5 minutes followed by 38 cycles of 95degreesC for 30 s, annealing temperature for 60 s and 72degreesC for 60 s, with a final extension step of 72degreesC for 10 minutes. Fluorescent automated cycle sequencing of the PCR products was performed using a dRhodamine terminator reaction kit (PE Biosystems, Warrington, UK). Electrophoresis was performed on polyacrylamide gels using the ABI PRISM(R) 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA) and the sequence analyzed utilizing ABI PRISM(R) 377 sequencing software.
###end p 15
###begin title 16
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
FCGR genotyping
###end title 16
###begin title 17
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
FCGR2A
###end title 17
###begin p 18
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 212 214 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 410 416 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 460 462 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 604 606 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 715 721 713 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 801 807 799 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 843 850 841 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 854 860 852 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
The FCGR2A-131H/R functional polymorphism has a G-->A substitution at nucleotide 519, which results in a switch from arginine (R) to histidine (H) at amino acid position 131 in the immunoglobulin-binding domain [28]. Genotyping was performed using a nested amplification refractory mutation system (ARMS) PCR approach. A 322 bp PCR product was amplified (30 cycles) using a combination of previously published FCGR2A-specific primer sequences (PCR1 and 4INM) [28]. A 1:500 dilution served as a template for two separate nested ARMS PCRs that utilized 400 nmol/l of the published IIA-R and IIA-H primers [29]. The 322 bp product served as a positive control and a 246 bp product indicated the presence of either the FCGR2A-131H or R allele, according to the ARMS primer used. Specific amplification of FCGR2A, rather than the highly homologous FCGR2B and FCGR2C, and the +519 SNP, was confirmed in 40 individuals by direct sequencing.
###end p 18
###begin title 19
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
FCGR2B
###end title 19
###begin p 20
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B-</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 293 296 293 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
###xml 391 394 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
The FCGR2B-1206G/A polymorphism was genotyped using a nested RFLP assay. The 330 bp FCGR2B-specific sequencing PCR product (see above) was diluted 1:200 and served as a template for a second PCR that used IIB-UTRSF and a mutated reverse primer (IIB-UTRGR), which introduced an allele-specific HaeIII restriction site. The resultant PCR product was incubated at 37degreesC for 1 hour with 6U HaeIII (Promega) and the products visualized using a 3.5% agarose gel.
###end p 20
###begin title 21
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
FCGR3A
###end title 21
###begin p 22
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Additional DNA samples that had not yielded reliable results on direct sequencing [11] were genotyped using our single-stranded conformational polymorphism assay [12] and were included in the haplotype analysis.
###end p 22
###begin title 23
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
FCGR3B
###end title 23
###begin p 24
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 337 344 337 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 348 356 348 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B) </italic>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCSD1</italic>
The functional neutrophil antigen (NA)1 and NA2 alleles of FCGR3B were genotyped using minor modifications to a previously published ARMS PCR assay, which included both allele-specific primers and a distinct internal control [30]. The NA1 assay included the two ARMS primers IIIB-NA1F and IIIB-NA1R, and an internal control (fragment of FCGR3A and FCGR3B) was amplified by IIIB-NA1PF and IIIB-NA1PR. The NA2 assay similarly included the IIIB-NA2F and IIIB-NA2R ARMS primers and internal control primers IIIB-NA2PR and IIIB-NA2PR from the gene MCSD1.
###end p 24
###begin title 25
Statistical analyses
###end title 25
###begin p 26
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Statistical analyses were performed using the Stata statistical software (Stata Statistical Software, release 8.0; Stata Corporation, College Station, TX, USA) unless otherwise stated. Hardy-Weinberg equilibrium was investigated in each control population using a goodness-of-fit test to check whether the observed pattern of genotype frequencies was consistent with expectations. Allele and genotype frequencies were compared using 2 x 2 and 3 x 2 contingency tables, respectively. Nodules are only rarely present during the early stages of RA and their absence does not indicate that they may not develop in the future. The control population was therefore felt to be the most appropriate reference group for analysis of the subgroup with nodular RA [31].
###end p 26
###begin p 27
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Haplotype frequencies were estimated pair-wise across the FCGR locus using the Estimating Haplotypes PLUS (EHPLUS) program [32]. A pair-wise measure of linkage disequilibrium (D') was also calculated for each pair of FCGR genes. Association with disease was tested for by comparing the haplotype frequencies estimated from cases and controls separately with estimates based on the combined sample, using a likelihood ratio test. A permutation procedure implemented in the EHPLUS program was used to assess statistical significance based on 1,000 permutations [32].
###end p 27
###begin p 28
###xml 153 167 153 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 821 826 821 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
If an individual is heterozygous at two loci, then the phase (for example, which variants are inherited from the same parent) is unknown. Association of FCGR3A-FCGR3B haplotypes with RA was investigated further using the haplotype trend regression (HTR) approach proposed by Zaykin and coworkers [33] for dealing with uncertain phase. In this method logistic regression can be used to predict disease status from an individual's haplotypes; where these are not known with certainty, all haplotypes consistent with the genotypes are included as predictors, weighted by their probabilities. This approach estimates the effect on risk for each haplotype, assuming that each of the individual's two haplotypes can have an independent effect. Stepwise regression analyses were also used to investigate the joint effect of the FCGR genes [34].
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Chromosomal order of the FCGR genes
###end title 30
###begin p 31
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
###xml 150 157 150 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 326 332 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 489 495 489 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 497 503 497 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
The FCGR genes were located on three BAC clones: RP11-474I16 (EMBL: AL359541) contained FCGR2B; RP11-25I17 (EMBL: AC021370) contained FCGR2B, FCGR2C, FCGR3A and FCGR3B; and the final clone RP11-5K23 (EMBL: AC013307) contained FCGR3A and FCGR2A. The complete genomic sequence of each FCGR (with the exception of the 5' part of FCGR2C) was identified on these BAC clones. Alignment of the sequence fragments demonstrated the FCGR gene order from centromere to telomere at chromosome 1q23 as FCGR2A, FCGR3A, FCGR2C, FCGR3B, FCGR2B. Similar work is in agreement with this gene order [35].
###end p 31
###begin title 32
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
FCGR2B sequencing
###end title 32
###begin p 33
###xml 108 110 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 151 157 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 241 248 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
The rs844 G-->A substitution was confirmed and was identical to that described previously at position 1206 [26], and this SNP was therefore designated FCGR2B-1206G/A. No further polymorphisms were identified in exons 3 or 6 or the 3'-UTR of FCGR2B in 30 control individuals and RA patients.
###end p 33
###begin title 34
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
Association of FCGR2A, FCGR3B and FCGR2B with rheumatoid arthritis
###end title 34
###begin p 35
###xml 154 161 154 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> FCGR2A</italic>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 174 181 174 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 240 247 240 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 314 316 314 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 362 364 362 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Genotyping was complete on 274 Caucasian individuals (147 cases and 127 controls) and 249 North Indian/Pakistani individuals (122 cases and 127 controls). FCGR2A, FCGR3A and FCGR2B were in Hardy-Weinberg equilibrium in both control groups. FCGR3B was not in Hardy-Weinberg equilibrium (for the UK Caucasian group: P = 0.01; for the North Indian/Pakistani group: P = 0.002). We subsequently sequenced more than 200 individuals with 100% agreement with our genotyping assays to exclude genotyping error as an explanation.
###end p 35
###begin p 36
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 420 422 420 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 500 502 500 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
No significant differences in the allele or genotype distributions were seen for FCGR2A, FCGR3B, or FCGR2B in either RA group compared with controls (Table 2). The results for FCGR3A in our expanded UK Caucasian cohort were consistent with our previous findings [11]. Homozygosity for the FCGR3A-158V allele demonstrated a trend toward and association with RA (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.0-4.7; P = 0.06) and significant association with nodular RA (OR 4.3, 95% CI 1.5-12.3; P = 0.005).
###end p 36
###begin title 37
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Linkage disequilibrium at the FCGR genetic locus
###end title 37
###begin p 38
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 62 64 62 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 244 251 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 286 289 286 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 298 300 298 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 333 336 333 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 345 347 345 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 371 374 371 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 550 557 550 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 561 568 561 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 601 604 601 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
There was evidence of weak linkage disequilibrium (D' = 0.30, P = 0.01) between FCGR2A and FCGR3A in the UK Caucasian but not the North Indian/Pakistani control populations. Highly significant linkage disequilibrium was seen between FCGR3B and FCGR2B in both populations (UK Caucasian: D' = -0.68, P = 0.0001; North Indian/Pakistani:D' = -0.52, P = 0.0001). The negative D' values indicate linkage disequilibrium between the common allele of one gene and the rare allele of the second gene. No significant linkage disequilibrium was detected between FCGR3A and FCGR3B in either ethnic group, although D' = 0.40 in the UK Caucasian group (Table 3).
###end p 38
###begin title 39
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Association of FCGR haplotypes with rheumatoid arthritis
###end title 39
###begin p 40
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 174 188 174 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 247 261 247 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
The distributions of two locus FCGR haplotypes were compared between the RA cohorts and their control populations, with a difference approaching statistical significance for FCGR3A-FCGR3B (Table 4). Compared with the control frequency of 24%, the FCGR3A-FCGR3B 158V-NA2 haplotype was found at increased frequency in UK Caucasian RA patients (31%) and even higher frequency in those with nodular RA (37%).
###end p 40
###begin p 41
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
From the HTR analysis of FCGR3A-FCGR3B haplotypes, the 158V-NA2 haplotype was found to have a significant effect on the risk for RA in UK Caucasians (OR 1.77, 95% CI 1.09-2.87; P = 0.02), taking the most common haplotype (158F-NA2) as baseline (Table 5). The effect was stronger in the small subgroup of UK Caucasian individuals with nodules (OR 2.51, 95% CI 1.15-5.49; P = 0.02).
###end p 41
###begin p 42
###xml 521 523 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 691 693 691 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
These are estimates of the effect of each haplotype, assuming that each of the individual's two haplotypes has an independent effect on risk with a combined multiplicative effect. The effect of the 158V-NA2 haplotype was found to be largely confined to those with two copies of this haplotype (data not shown). To estimate the effect under a recessive model, homozygosity for this haplotype was compared in the control population (frequency 4%) with the total RA population (11%), giving an OR of 3.18 (95% CI 1.13-8.92; P = 0.03) when comparing homozygotes with all others. Again, the effect of homozygosity was stronger in those with nodular RA (frequency 16%; OR 5.03, 95% CI 1.44-17.56; P = 0.01).
###end p 42
###begin p 43
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
For the North Indian/Pakistani cohort the same haplotype was found to be at increased frequency in RA patients compared with controls (OR 1.52, 95% CI 0.82-2.80, from the HTR analysis) but the difference was not statistically significant (P = 0.19; Table 5). Homozygosity for this haplotype was seen in approximately 4% of the RA and 1.5% of the control population.
###end p 43
###begin title 44
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
Stepwise logistic regression analyses of FCGR3A and FCGR3B in the Caucasian group
###end title 44
###begin p 45
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 192 199 192 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 248 255 248 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 259 261 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 319 321 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 390 397 388 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 438 440 436 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Considering each locus separately, FCGR3A is associated with RA in Caucasians [11] but FCGR3B is not (Table 2). However comparing the model containing both genotypes with the model containing FCGR3A only, there is an improved fit with inclusion of FCGR3B (chi2 = 6.27, 2 degrees of freedom, from likelihood ratio test; P = 0.04). When the cohort with nodules was examined, the inclusion of FCGR3B did not significantly improve the model (P = 0.22).
###end p 45
###begin title 46
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Contribution of FCGR haplotypes and shared epitope alleles in rheumatoid arthritis susceptibility
###end title 46
###begin p 47
###xml 493 498 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 679 685 679 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 686 693 686 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3 </italic>
One advantage of the HTR framework for analysis of haplotypes is that other factors can be included in the model. The analysis was repeated including the RA-associated 'shared epitope' (SE) alleles (positive or negative) in the models. As expected, the SE itself was still highly predictive of RA in these models (OR 3.16, 95% CI 1.75-5.71 in UK Caucasians; OR 3.94, 95% CI 2.17-7.18 in the North Indian/Pakistani group). There was evidence of a multiplicative joint effect between SE and the FCGR haplotypes, consistent with both of these two genetic factors contributing to the risk for disease. Thus, the risk for RA in SE-positive UK Caucasian individuals homozygous for the FCGR3A-FCGR3B 158V-NA2 haplotype is increased tenfold compared with those with other FCGR3 genotypes who are SE negative.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 474 488 474 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 520 527 520 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 706 720 706 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
###xml 908 910 908 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1120 1126 1120 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1136 1142 1136 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 1226 1228 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1273 1280 1273 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 1321 1323 1321 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1531 1537 1531 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1538 1545 1538 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
Haplotype analyses have started to assume an increased importance in genetic studies of human disease because they can be more informative in their ability to identify unique chromosomal segments that are likely to harbour disease predisposing genes. They may also provide additional evidence for the presence of further unidentified polymorphic variants that are the true disease-susceptibility variants [36]. We have demonstrated an increased level of association between FCGR3A-FCGR3B haplotypes and RA compared with FCGR3A alone. The effects were stronger in the subset of RA patients with nodules. The two-locus haplotype showing the strongest association with RA susceptibility in each group was the FCGR3A-FCGR3B 158V-NA2 haplotype. UK Caucasian individuals who were homozygous for this haplotype were estimated to be at threefold risk for disease compared with all others (OR 3.18, 95% CI 1.13-8.92; P = 0.03), and this analysis does not depend on inference of uncertain phase because individuals that are homozygous for a haplotype are unambiguously identified by their genotype. The relative importance of the FCGR3A-158V and FCGR3B-NA2 polymorphic variants were assessed further using stepwise regression analyses [34]. These analyses showed that, although only FCGR3A has been shown to be associated with RA [11], the model including both loci provided an improved fit for RA susceptibility, but not necessarily so for the development of nodules. In the North Indian/Pakistani population there was a 6% increase in the FCGR3A-FCGR3B 158V-NA2 haplotype, but this failed to reach statistical significance.
###end p 49
###begin p 50
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
Several methods have been proposed for the analysis of such data in the absence of family data and the consequent presence of phase uncertainty. The HTR method we have chosen to use has various advantages. The method uses all the data, including that from individuals with uncertain phase. Because the data are analyzed in a regression framework, the usual regression diagnostics are available, other factors can be included in the model and tests for interaction can be performed. A potential disadvantage of the method is that weights used in the regression analysis are based on estimated haplotype frequencies, and the uncertainty inherent in the estimates is ignored in the model. This leads to an anti-conservative test and could lead to false-positive results. However, Stram and coworkers [37] evaluated the method in comparison with other more sophisticated approaches and found it to perform well in most situations.
###end p 50
###begin p 51
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
Haplotype frequencies were estimated using the expectation-maximization algorithm, which has been shown to perform well, even in the presence of some departure from Hardy-Weinberg equilibrium [38]. Errors due to sampling are generally of much greater concern than inaccuracies due to the estimation process.
###end p 51
###begin p 52
###xml 278 284 <span type="species:ncbi:9606">humans</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
We acknowledge that none of our results are highly statistically significant when a consideration is made for multiple tests. However, the consistent pattern of results, taken in conjunction with prior findings in relation to these genes and their known biological functions in humans and mice, gives additional credence to them. Replication of these findings in other populations will ultimately be required.
###end p 52
###begin p 53
###xml 222 229 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 364 366 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 367 369 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 514 515 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 516 517 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 679 681 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 858 860 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 861 863 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 879 888 851 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1093 1095 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1214 1221 1174 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 1424 1426 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1560 1566 1512 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1567 1574 1519 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 1653 1655 1605 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1656 1658 1608 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1659 1661 1611 1613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1662 1664 1614 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 375 381 <span type="species:ncbi:9606">humans</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 916 924 <span type="species:ncbi:9606">patients</span>
The FcgammaRs play important roles in the initiation and propagation of many different immunological and inflammatory processes. Consequently, they may act as susceptibility factors for RA through a variety of mechanisms. FCGR3A was the most significant gene in this study, and we have previously discussed the role that this receptor may play in RA pathogenesis [11,12]. In humans, FcgammaRIIIa is expressed on natural killer cells, macrophages, gammadelta T cells, a subset of monocytes and cultured mast cells [5,6]. Higher levels of FcgammaRII and FcgammaRIII expression have been demonstrated in synovial biopsy specimens from RA patients compared with control individuals [39]. Similarly, an increase in the expression level and proportion of circulating FcgammaRIIIa-positive monocytes has been observed in RA and may correlate with disease activity [40,41]. In addition, in vitro derived macrophages from RA patients expressed more FcgammaRII and FcgammaRIIIa, and released higher levels of tumour necrosis factor-alpha and matrix degrading enzymes in response to heat-aggregated IgG [39] compared with controls. These findings are supportive of our own work whereby the higher affinity genetic variant of FCGR3A may sensitize FcgammaR-bearing cells to IgG-containing immune complexes. FcgammaRIIIa may also play an important role delivering (auto)antigens, and activation and maturation signals to dendritic cells [42]. This may provide an explanation for the over tenfold increased risk for RA in SE-positive Caucasian individuals homozygous for the FCGR3A-FCGR3B 158V-NA2 haplotype, which has been a consistent finding by a number of groups [11-13,15,18].
###end p 53
###begin p 54
###xml 253 254 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 255 256 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 507 509 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 510 512 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 514 522 498 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> FCGR3B </italic>
###xml 750 756 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 842 848 826 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 866 868 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1072 1073 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1074 1076 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1126 1133 1110 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 1153 1155 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1156 1158 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1197 1204 1181 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 1264 1266 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1580 1582 1564 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
FcgammaRIIIb is selectively expressed on neutrophils and eosinophils, and has a low affinity for IgG. It is linked to the membrane by a glycosylphosphatidylinositol anchor and does not appear to associate with the known transmembrane adapter molecules [5,6]. However, FcgammaRIIIb appears to interact with FcgammaRIIa in the phagocytosis of immune complexes and subsequent cellular activation, with signalling being mediated through the ITAM (immunoreceptor tyrosine-based activation motif) of FcgammaRIIa [43,44]. FCGR3B has two common polymorphic forms, namely NA1 and NA2, which differ in five nucleotides that produce four amino acid differences. This alters the number of glycosylation sites, and neutrophils from individuals homozygous for the FCGR3B-NA2 allele have been found consistently to exhibit lower levels of phagocytosis than FCGR3B-NA1 homozygotes [45]. This polymorphism has important biological consequences, especially in the development of blood transfusion reactions, autoimmune neutropenias and the severity of renal disease in systemic vasculitis [6,46]. Individuals with duplications and deletions of FCGR3B have been reported [30,47], with the estimated frequency of the FCGR3B deletion being 0.001-0.08 in various Caucasian populations [48]. Standard genotyping assays, as performed in the present study, do not allow a calculation of the gene copy number. This may provide an explanation for a failure of our control populations to conform to Hardy-Weinberg equilibrium and the previously reported non-Mendelian segregation in some Caucasian families [49].
###end p 54
###begin p 55
###xml 156 158 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 159 161 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 211 217 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 222 228 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 355 362 351 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 380 382 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 128 134 <span type="species:ncbi:10090">murine</span>
FcgammaRIIb plays a crucial role in the regulation of antibody production and susceptibility to several spontaneous and induced murine autoimmune diseases [50-52]. We found no evidence of an association between FCGR2B- or FCGR2B-containing haplotypes and RA in our cohorts, unlike previous observations in a Japanese cohort in which an alternative SNP in FCGR2B was investigated [15].
###end p 55
###begin title 56
Conclusion
###end title 56
###begin p 57
###xml 339 344 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 565 572 561 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 610 624 606 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A&#8211;FCGR3B </italic>
There is good data that FcgammaRs may be critical modulators of inflammation within the synovium and that subtle changes in either expression or structure of these receptors may influence both the susceptibility to RA and the development of nodules. The analyses performed in this study have strengthened our original observation that the FCGR genetic locus is associated with RA, particularly in a UK Caucasian population with nodular disease. Our haplotype data, together with the stepwise regression analysis, suggest that additional polymorphic variants within FCGR3A or in linkage disequilibrium with the FCGR3A-FCGR3B 158V-NA2 haplotype may contribute to RA pathogenesis.
###end p 57
###begin title 58
Abbreviations
###end title 58
###begin p 59
ARMS = amplification refractory mutation system; BAC = bacterial artificial chromosome; bp = base pairs; BLAST = basic local alignment search tool; CI = confidence interval; FcgammaR = Fcgamma receptor; HTR = haplotype trend regression; NA = neutrophil antigen; OR = odds ratio; PCR = polymerase chain reaction; RA = rheumatoid arthritis; RF = rheumatoid factor; SE = shared epitope; SNP = single nucleotide polymorphism; UTR = untranslated region.
###end p 59
###begin title 60
Competing interests
###end title 60
###begin p 61
The authors declare that they have no competing interests.
###end p 61
###begin title 62
Authors' contributions
###end title 62
###begin p 63
###xml 333 341 <span type="species:ncbi:9606">patients</span>
AWM participated in the design of the study, undertook all database searches, oversaw all aspects of the laboratory work, analyzed the data and prepared the manuscript. JHB gave additional statistical support and performed the haplotype analysis. BG, RDS and PE participated in the collection of clinical data and the recruitment of patients into the study. DS, JR and VK undertook some of the genotyping assays on DNA prepared in the laboratory of EAJ and RWO, who participated in the original design of the study. FP and MA gave invaluable advice during the retrieval of sequence data from the public databases and during the optimization of some genotyping assays. AWB, AFM, PE and JDI participated in the design of the study, interpretation of the results and writing of the final manuscript.
###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
This work was supported by grants from the Arthritis Research Campaign and the Medical Research Council, UK. In addition, the authors would like to acknowledge Dr Philip Gardner for performing some DNA extractions and helpful discussions with Dr Ian Carr regarding some laboratory aspects of this project.
###end p 65
###begin article-title 66
Familial clustering of rheumatoid arthritis with other autoimmune diseases
###end article-title 66
###begin article-title 67
Autoimmunity in rheumatoid arthritis
###end article-title 67
###begin article-title 68
Prognostic laboratory markers of joint damage in rheumatoid arthritis
###end article-title 68
###begin article-title 69
Are autoantibodies active players or epiphenomena?
###end article-title 69
###begin article-title 70
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease
###end article-title 70
###begin article-title 71
Inflammation in autoimmunity: receptors for IgG revisited
###end article-title 71
###begin article-title 72
###xml 75 80 <span type="species:ncbi:9606">human</span>
Differential modulation of stimulatory and inhibitory Fcgamma receptors on human monocytes by Th1 and Th2 cytokines
###end article-title 72
###begin article-title 73
Immune inhibitory receptors
###end article-title 73
###begin article-title 74
Coordinate expression of activating Fcgamma receptors I and III and inhibiting Fcgamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis
###end article-title 74
###begin article-title 75
Induction and suppression of collagen-induced arthritis is dependent on distinct Fcgamma receptors
###end article-title 75
###begin article-title 76
Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups
###end article-title 76
###begin article-title 77
FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study
###end article-title 77
###begin article-title 78
Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis
###end article-title 78
###begin article-title 79
The F158V polymorphism in FcgammaRIIIA shows disparate associations with rheumatoid arthritis in two genetically distinct populations
###end article-title 79
###begin article-title 80
Studies on the association of Fcgamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A
###end article-title 80
###begin article-title 81
Immunoglobulin G Fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis
###end article-title 81
###begin article-title 82
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms in Spanish rheumatoid arthritis patients: an association and linkage study
###end article-title 82
###begin article-title 83
Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis
###end article-title 83
###begin article-title 84
Association study designs for complex diseases
###end article-title 84
###begin article-title 85
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients
###end article-title 85
###begin article-title 86
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Racial origin and its effect on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched cross-sectional study
###end article-title 86
###begin article-title 87
National Center for Biotechnology Information (NCBI)
###end article-title 87
###begin article-title 88
Ensembl
###end article-title 88
###begin article-title 89
Computational Biology at Oak Ridge National Laboratory (ORNL)
###end article-title 89
###begin article-title 90
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Organisation of the human and mouse low-affinity FcgammaR genes: duplication and recombination
###end article-title 90
###begin article-title 91
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 56 62 <span type="species:ncbi:10090">murine</span>
###xml 67 72 <span type="species:ncbi:9606">human</span>
Interaction of a human FcgammaRIIb1 (CD32) isoform with murine and human IgG subclasses
###end article-title 91
###begin article-title 92
###xml 23 28 <span type="species:ncbi:9606">human</span>
Functional analysis of human FcgammaRII (CD32) isoforms expressed in B lymphocytes
###end article-title 92
###begin article-title 93
###xml 55 59 51 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">127 </sup>
A naturally occurring mutation in FcgammaRIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor
###end article-title 93
###begin article-title 94
FcgammaRIIa polymorphism in systemic lupus erythematosus
###end article-title 94
###begin article-title 95
Neutrophil FcgammaRIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families
###end article-title 95
###begin article-title 96
Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Reply
###end article-title 96
###begin article-title 97
Model-free analysis and permutation tests for allelic associations
###end article-title 97
###begin article-title 98
Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals
###end article-title 98
###begin article-title 99
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in Type 1 diabetes
###end article-title 99
###begin article-title 100
###xml 34 39 <span type="species:ncbi:9606">human</span>
Genomic organization of classical human low-affinity Fcgamma receptor genes
###end article-title 100
###begin article-title 101
Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease
###end article-title 101
###begin article-title 102
Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals
###end article-title 102
###begin article-title 103
Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximisation algorithm for unphased diploid genotype data
###end article-title 103
###begin article-title 104
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase
###end article-title 104
###begin article-title 105
Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis
###end article-title 105
###begin article-title 106
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rates who do not use anti-rheumatic drugs
###end article-title 106
###begin article-title 107
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalisation
###end article-title 107
###begin article-title 108
###xml 84 89 <span type="species:ncbi:9606">human</span>
Convergence of Fcgamma receptor IIA and Fcgamma receptor IIIB signaling pathways in human neutrophils
###end article-title 108
###begin article-title 109
Fcgamma receptor IIIb enhances Fcgamma receptor IIa function in an oxidant-dependent and allele-sensitive manner
###end article-title 109
###begin article-title 110
###xml 25 30 <span type="species:ncbi:9606">human</span>
Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities
###end article-title 110
###begin article-title 111
Receptors for immunoglobulin G. Molecular diversity and implications for disease
###end article-title 111
###begin article-title 112
Fc gamma RIIIB gene duplication: evidence for presence and expression of three distinct Fc gamma RIIIB genes in NA(1+,2+)SH(+) individuals
###end article-title 112
###begin article-title 113
The polymorphonuclear neutrophil Fc gamma RIIIb deficiency is more frequent than hitherto assumed
###end article-title 113
###begin article-title 114
Association of Fcgamma receptor IIA, but not IIB and IIIA, polymorphisms with systemic lupus erythematosus: A family-based association study in Caucasians
###end article-title 114
###begin article-title 115
Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility
###end article-title 115
###begin article-title 116
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII
###end article-title 116
###begin article-title 117
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes
###end article-title 117
###begin title 118
Figures and Tables
###end title 118
###begin p 119
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Primer pairs used to amplify specific FCGR sequencing templates
###end p 119
###begin p 120
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 128 131 128 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
The mutation inserted into the FCGR2B reverse nested primer (IIB-UTRGR) is shown in italics. This introduced an allele-specific HaeIII restriction site (GGCC) in the presence of the G but not the A allele.
###end p 120
###begin p 121
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Genotype frequencies in UK Caucasian and North Indian/Pakistani rheumatoid arthritis patients and healthy controls
###end p 121
###begin p 122
Values are expressed as number (%). RA, rheumatoid arthritis.
###end p 122
###begin p 123
###xml 43 45 43 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D'</italic>
Pair-wise linkage disequilibrium measures (D') calculated from the control groups in the two populations
###end p 123
###begin p 124
###xml 10 13 10 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
Shown are D' measures for the UK Caucasian (and North Indian/Pakistani) populations. Values with a magnitude of 0.3 and higher highlighted in bold.
###end p 124
###begin p 125
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Estimated pairwise haplotype frequencies in rheumatoid arthritis patients and healthy controls
###end p 125
###begin p 126
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 221 227 221 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 269 271 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Pairwise haplotypes produced from four biallelic markers (FCGR2A-131H/R, FCGR3A-158F/V, FCGR3B-NA2/1 and FCGR2B-1206G/A) denoted in the order they occur at the FCGR locus. Thus, 131R-158F indicates a haplotype containing FCGR2A-131R and FCGR3A-158F alleles. aEmpirical P values obtained from a heterogeneity test statistic incorporated in the PM program after 1,000 permutations. RA, rheumatoid arthritis.
###end p 126
###begin p 127
###xml 85 99 85 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A-FCGR3B </italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Haplotype trend regression in rheumatoid arthritis patients and healthy controls for FCGR3A-FCGR3B haplotypes
###end p 127
###begin p 128
Values are expressed as odds ratio (95% confidence interval). RA, rheumatoid arthritis.
###end p 128

